Showing 1-10 of about 67 articles.
Evelo Biosciences, Inc.
-- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- -- Accelerate delivery of interim clinical data from EDP1815 Phase 2 psoriasis trial...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates...
Evelo Biosciences, Inc.
–EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503––Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product...
Evelo Biosciences, Inc.
–Treatment with EDP1815 demonstrates statistically and clinically significant improvement in mean EASI and IGA* BSA scores––EDP1815 first-ever candidate targeting SINTAX™ to show clinical activity in...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act...
Evelo Biosciences, Inc.
-- EDP1908 demonstrates potent anti-tumor effects in murine models of cancer -- -- Oral extracellular vesicles have potential to be a completely novel mechanism of I/O therapy -- CAMBRIDGE, Mass.,...
Evelo Biosciences, Inc.
-- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis ---- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Showing 1-10 of about 67 articles.
